DHR

Danaher Corp. (DHR) | Rumor.io

Danaher

DHR

Attention (50-day avg)0%

Attention rank (50-day avg)#940

Bullish sentiment (50-day avg)62%

Price to earnings ratio40.4

Market capitalization159.8B

Earnings per share5.61

Dividend yield (TTM)0.7%

Revenue (annual)24.6B

Net income (annual)3.6B

Social

What share of all stock conversation is about DHR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% 0	0.01% +0

Jul 23

Danaher Corporation ($DHR) has a strong bioprocessing segment, with orders up over 30% earlier this year, driven by pharmaceutical manufacturing demand.
Danaher's price action is holding a key support pivot near $178.72, backed by institutional option activity, including notable sweeps on the 8-hour chart.
The company's earnings report showed revenue growth of 10% and organic growth of 5%, with lab/biopharma segment up 12%, and adjusted EPS of $6.03.

Generated by AI

Sentiment

Of the messages about DHR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	58.56% -28.94	86.37% +15.38
Bearish	—	0% 0	41.44% +28.94	13.63% -15.38

Bullish· Jan 28

Danaher Corporation's Q4 2025 earnings showed a strong beat, with adjusted EPS of $2.23 and revenue of $6.8B, driven by outperformance in Bioprocessing and positive momentum in Diagnostics and Life Sciences.
The company's guidance for FY26 is optimistic, with core revenue growth expected to be 3-6% and EPS of $8.35-$8.50.
Danaher's Biotechnology segment saw a 9% revenue boost in Q4, fueling the positive momentum, and the company expects to see further growth in this area in 2026.

Bearish· Jan 29

$DHR's recent quarter was uncharacteristically weak, with biotech segment underperforming.
The company faces a 2% FX headwind in FY25 due to a strong US dollar, and its Q1'25 core revenue is expected to decline in the low single digits.
$DHR's valuation is high, with the stock trading at 40-50x multiple, despite industry headwinds and concerns about the company's ability to deliver earnings growth.

Generated by AI

Topics

Of the messages about DHR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	97.3%	64.37%	2.09%
Technical Analysis	100%	2.7%	20.24%	0.96%
Macro	0%	0%	14.17%	47.76%
Analysts	0%	0%	0.4%	47.33%
Earnings	0%	0%	0.81%	1.85%
Controversies	0%	0%	0%	0.01%

Earnings· Jul 21

Danaher Corporation reported Q2 2026 earnings with adjusted EPS of $1.94, beating the estimated $1.84, and revenue of $6.27B, surpassing the estimated $6.27B.
The company raised its full-year 2026 adjusted EPS guidance to $8.45-$8.60, driven by closing the $9.9B Masimo acquisition early and bioprocessing orders growing mid-teens.
Despite beating earnings estimates, Danaher's stock price dropped 14%, erasing nearly $20 billion in equity value, due to a gap between bioprocessing orders and actual sales, raising concerns about the company's future performance.

Analysts· Apr 27

Danaher Corporation ($DHR) has been maintained with a Buy rating by Deutsche Bank, with a lowered price target of $275.
William Blair has given Danaher ($DHR) an Outperform rating, with multiple analysts reaffirming this rating.
Multiple analysts have cut their price targets for Danaher ($DHR), including Robert W. Baird to $275.00 and Royal Bank of Canada to $260.00.

Announcements· Apr 21

$DHR reported Q1 2026 revenue of $6.0B, up 3.5% YoY, with adjusted EPS of $2.06, a 9.5% increase.
Danaher Corporation raised its FY26 guidance for adjusted EPS to $8.35-$8.55, and announced plans to acquire Masimo.
The company's strong cash flow and acquisition plans have been highlighted as key drivers of its growth, with the CEO stating that the team executed well in the first quarter.

Generated by AI

Community

Of the messages about DHR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85%	30.05%	54.68%	22.72%
Newcomers	15%	69.95%	45.32%	77.28%

Regulars· Jul 21

Danaher Corporation ($DHR) reported Q2 2026 earnings that topped Wall Street expectations, with revenue of $6.3B and adjusted EPS of $1.94, an 8% YoY increase.
Despite the strong earnings, the company lowered its 2026 core revenue growth forecast to 3-4% from 3-6%, and trimmed its outlook for its Bioprocessing business.
Regulars are questioning the leadership's cautious tone, with some calling for a more confident approach, and others pointing out that the CEO's "abundance of caution" predictions haven't come true in the past.

Newcomers· Jul 22

Newcomers to Danaher stock are questioning the company's recent performance, with some pointing to a 30% decline in value over the past 5 years and a recent sell-off following lackluster 2Q 2026 earnings.
Analysts are debating Danaher's valuation, with some using a proprietary indicator to spot when price and earnings are diverging, and others focusing on the company's ability to adapt to industry changes.
Some users are pointing to Danaher's position in the pharmaceutical industry as a potential catalyst for growth, citing the company's role in producing tools and infrastructure for drug production, and the potential for increased guidance and buildouts.

Generated by AI

Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]

1d agoYahoo Finance

Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR)

Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.

6d agoSeeking Alpha

Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth

Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...

6d agoYahoo Finance

Danaher Corp. stock outperforms competitors on strong trading day

7d agoMarketWatch

Danaher Schedules Third Quarter 2026 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.

7d agoYahoo Finance Singapore

Danaher Corp. stock outperforms competitors on strong trading day

8d agoMarketWatch

Also Discussed

Investors talking about DHR also mention

#	Name	Attention
1	Thermo Fisher Scientific Inc.TMO	0%0
2	Fortive CorporationFTV	0%0
3	Roper Technologies Inc.ROP	0%+0
4	Stryker CorporationSYK	0.01%+0.01
5	Mettler-Toledo International Inc.MTD	0%new
6	Manhattan Associates Inc.MANH	0%0
7	S&P Global Inc.SPGI	0.32%+0.21
8	Pentair plcPNR	0%0
9	Xylem Inc.XYL	0%-0.01
10	Watsco Inc.WSO	0%0

Danaher Corp.

Healthcare
Diagnostics & Research

Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business is organized around Biotechnology, Life Sciences, and Diagnostics, with offerings that support areas such as biologics manufacturing, molecular and clinical diagnostics, genomics, and analytical instrumentation. Danaher serves customers across healthcare, research, and industrial settings, helping laboratories and life sciences organizations improve efficiency, precision, and productivity. Headquartered in Washington, D.C., Danaher operates through a portfolio of specialized operating companies that provide products and solutions for scientific discovery, disease detection, and the production of biologic therapies.

Website

Location

2200 Pennsylvania Avenue N.W.

Washington, DC, 20037-1701

United States

Social

What share of all stock conversation is about DHR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% 0	0.01% +0

Jul 23

Danaher Corporation ($DHR) has a strong bioprocessing segment, with orders up over 30% earlier this year, driven by pharmaceutical manufacturing demand.
Danaher's price action is holding a key support pivot near $178.72, backed by institutional option activity, including notable sweeps on the 8-hour chart.
The company's earnings report showed revenue growth of 10% and organic growth of 5%, with lab/biopharma segment up 12%, and adjusted EPS of $6.03.

Generated by AI

Sentiment

Of the messages about DHR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	58.56% -28.94	86.37% +15.38
Bearish	—	0% 0	41.44% +28.94	13.63% -15.38

Bullish· Jan 28

Danaher Corporation's Q4 2025 earnings showed a strong beat, with adjusted EPS of $2.23 and revenue of $6.8B, driven by outperformance in Bioprocessing and positive momentum in Diagnostics and Life Sciences.
The company's guidance for FY26 is optimistic, with core revenue growth expected to be 3-6% and EPS of $8.35-$8.50.
Danaher's Biotechnology segment saw a 9% revenue boost in Q4, fueling the positive momentum, and the company expects to see further growth in this area in 2026.

Bearish· Jan 29

$DHR's recent quarter was uncharacteristically weak, with biotech segment underperforming.
The company faces a 2% FX headwind in FY25 due to a strong US dollar, and its Q1'25 core revenue is expected to decline in the low single digits.
$DHR's valuation is high, with the stock trading at 40-50x multiple, despite industry headwinds and concerns about the company's ability to deliver earnings growth.

Generated by AI

Topics

Of the messages about DHR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	97.3%	64.37%	2.09%
Technical Analysis	100%	2.7%	20.24%	0.96%
Macro	0%	0%	14.17%	47.76%
Analysts	0%	0%	0.4%	47.33%
Earnings	0%	0%	0.81%	1.85%
Controversies	0%	0%	0%	0.01%

Earnings· Jul 21

Danaher Corporation reported Q2 2026 earnings with adjusted EPS of $1.94, beating the estimated $1.84, and revenue of $6.27B, surpassing the estimated $6.27B.
The company raised its full-year 2026 adjusted EPS guidance to $8.45-$8.60, driven by closing the $9.9B Masimo acquisition early and bioprocessing orders growing mid-teens.
Despite beating earnings estimates, Danaher's stock price dropped 14%, erasing nearly $20 billion in equity value, due to a gap between bioprocessing orders and actual sales, raising concerns about the company's future performance.

Analysts· Apr 27

Danaher Corporation ($DHR) has been maintained with a Buy rating by Deutsche Bank, with a lowered price target of $275.
William Blair has given Danaher ($DHR) an Outperform rating, with multiple analysts reaffirming this rating.
Multiple analysts have cut their price targets for Danaher ($DHR), including Robert W. Baird to $275.00 and Royal Bank of Canada to $260.00.

Announcements· Apr 21

$DHR reported Q1 2026 revenue of $6.0B, up 3.5% YoY, with adjusted EPS of $2.06, a 9.5% increase.
Danaher Corporation raised its FY26 guidance for adjusted EPS to $8.35-$8.55, and announced plans to acquire Masimo.
The company's strong cash flow and acquisition plans have been highlighted as key drivers of its growth, with the CEO stating that the team executed well in the first quarter.

Generated by AI

Community

Of the messages about DHR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85%	30.05%	54.68%	22.72%
Newcomers	15%	69.95%	45.32%	77.28%

Regulars· Jul 21

Danaher Corporation ($DHR) reported Q2 2026 earnings that topped Wall Street expectations, with revenue of $6.3B and adjusted EPS of $1.94, an 8% YoY increase.
Despite the strong earnings, the company lowered its 2026 core revenue growth forecast to 3-4% from 3-6%, and trimmed its outlook for its Bioprocessing business.
Regulars are questioning the leadership's cautious tone, with some calling for a more confident approach, and others pointing out that the CEO's "abundance of caution" predictions haven't come true in the past.

Newcomers· Jul 22

Newcomers to Danaher stock are questioning the company's recent performance, with some pointing to a 30% decline in value over the past 5 years and a recent sell-off following lackluster 2Q 2026 earnings.
Analysts are debating Danaher's valuation, with some using a proprietary indicator to spot when price and earnings are diverging, and others focusing on the company's ability to adapt to industry changes.
Some users are pointing to Danaher's position in the pharmaceutical industry as a potential catalyst for growth, citing the company's role in producing tools and infrastructure for drug production, and the potential for increased guidance and buildouts.

Generated by AI

Danaher

Social

Jul 23

Bullish· Jan 28

Bearish· Jan 29

Earnings· Jul 21

Analysts· Apr 27

Announcements· Apr 21

Regulars· Jul 21

Newcomers· Jul 22

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR)

Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth

Danaher Corp. stock outperforms competitors on strong trading day

Danaher Schedules Third Quarter 2026 Earnings Conference Call

Danaher Corp. stock outperforms competitors on strong trading day

Also Discussed

Danaher Corp.

Company Information

Location

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Danaher Isn't Anything Special, Even After Absorbing Masimo (NYSE:DHR)

Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth

Danaher Corp. stock outperforms competitors on strong trading day

Danaher Schedules Third Quarter 2026 Earnings Conference Call

Danaher Corp. stock outperforms competitors on strong trading day

Also Discussed

Social

Jul 23

Bullish· Jan 28

Bearish· Jan 29

Earnings· Jul 21

Analysts· Apr 27

Announcements· Apr 21

Regulars· Jul 21

Newcomers· Jul 22